Antibodies from Escherichia coli
A Plückthun - The Pharmacology of Monoclonal Antibodies, 1994 - Springer
Antibody engineering is still at its very beginning. No matter what the goal of the study, it is
likely that a number of different ideas and variants of the recombinant antibody will have to …
likely that a number of different ideas and variants of the recombinant antibody will have to …
Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells
Tumor immunotherapy should increase both the number of T cells that kill the tumor and the
likelihood that those cells are activated at the tumor site. Bispecific monoclonal antibodies …
likelihood that those cells are activated at the tumor site. Bispecific monoclonal antibodies …
T-cell based cancer immunotherapy: direct or redirected tumor-cell recognition?
GDM Beun, CJH van Velde, GJ Fleuren - Immunology today, 1994 - cell.com
In development of strategies for immunotberapy of cancer a new emphasis is emerging,
termed T-cell retargeting, which involves artificial redirection of cytotoxic T lymphocytes …
termed T-cell retargeting, which involves artificial redirection of cytotoxic T lymphocytes …
Cytotoxic lymphocyte granzymes trigger a target cell internal disintegration pathway leading to cytolysis and DNA breakdown.
H Nakajima, PA Henkart - Journal of immunology (Baltimore, Md …, 1994 - journals.aai.org
Two approaches have been used to assess the hypothesis that granzymes secreted by
cytotoxic lymphocytes act within the target cells to trigger an internal disintegration pathway …
cytotoxic lymphocytes act within the target cells to trigger an internal disintegration pathway …
The LFA‐1/ICAM cell adhesion pathway is involved in tumor‐cell lysis mediated by bispecific monoclonal‐antibody‐targeted T lymphocytes
S Ferrini, S Sforzini, A Cambiaggi… - … journal of cancer, 1994 - Wiley Online Library
We investigated the role of the LFA‐1/ICAM, VLA‐4/VCAM‐1 and CD2/LFA‐3 adhesion
pathways in the cytolysis of tumor cells mediated by an anti‐EGF‐R/anti‐CD3 bispecific …
pathways in the cytolysis of tumor cells mediated by an anti‐EGF‐R/anti‐CD3 bispecific …
Antitumor × Anti-CD3 Bifunctional Antibodies Redirect T-Cells Activated in Vivo with Staphylococcal Enterotoxin B to Neutralize Pulmonary Metastases
C Penna, PA Dean, H Nelson - Cancer research, 1994 - AACR
T-cell antitumor activities are limited by the requirement of two specific major
histocompatibility complex restricted steps, T-helper cell activation and cytotoxic T …
histocompatibility complex restricted steps, T-helper cell activation and cytotoxic T …
Peptide‐antibody conjugates for tumour therapy: A MHC‐class‐II‐restricted tetanus toxin peptide coupled to an anti‐IG light chain antibody can induce cytotoxic lysis …
Z Yu, F Healy, D Valmori, P Escobar… - … journal of cancer, 1994 - Wiley Online Library
Anti‐idiotype antibody therapy of B‐cell lymphomas, despite numerous promising
experimental and clinical studies, has so far met with limited success. Tailor‐made …
experimental and clinical studies, has so far met with limited success. Tailor‐made …
Target cell death triggered by cytotoxic T lymphocytes: a target cell mutant distinguishes passive pore formation and active cell suicide mechanisms
DS Ucker, JD Wilson, LD Hebshi - Molecular and cellular biology, 1994 - Am Soc Microbiol
The role of the target cell in its own death mediated by cytotoxic T lymphocytes (CTL) has
been controversial. The ability of the pore-forming granule components of CTL to induce …
been controversial. The ability of the pore-forming granule components of CTL to induce …
Targeting therapy for glioma by LAK cells coupled with bispecific antibodies
M Hishii, T Nitta, M Ebato, K Okumura, K Sato - Journal of Clinical …, 1994 - Elsevier
Targeting of T cells or natural killer (NK) cells to tumours by using bispecific antibodies has
attracted increasing interest in the past few years. We treated 31 patients with malignant …
attracted increasing interest in the past few years. We treated 31 patients with malignant …
Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR
HHVR Claasen, AMM Eggermont, YA Nooyen… - Gynecologic …, 1994 - Elsevier
The bispecific antibodies (bs-mAbs) OV-TL 3/CD3 and OC/TR (MOv18/CD3) efficiently
mediate ovarian tumor cell lysis by cytotoxic T cells and activated peripheral blood …
mediate ovarian tumor cell lysis by cytotoxic T cells and activated peripheral blood …